Pluristem Therapeutics Inc. is a clinical-stage biotechnology company using placental cells and a unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for a broad spectrum of diseases.

Pluristem derives its cell products from human placental cells. These cells are converted into PLacental eXpanded (PLX) cells, which secrete therapeutic proteins in response to signals produced by damaged tissues. Pluristem’s pipeline targets multiple indications involving inflammation and ischemia, including peripheral artery disease, muscle injury, preeclampsia, and graft versus host disease. PLX cells require no tissue matching prior to administration, making them an “off-the-shelf” product.

The company’s GMP-certified in-house manufacturing facilities allow it to efficiently produce commercial quantities of homogeneous, clinical-grade PLX cells. Pluristem is currently the only company manufacturing large quantities of placenta-based cell products using a 3D bioreactor. Driving these development efforts is a management team dedicated to shaping the future of the company and of placenta-based cell therapies. The Pluristem team has many decades of industry and research experience and draws on this as it continues to progress towards company goals.

Contact Pluristem Therapeutics, Inc.
+972-74-710-8600
info@pluristem.com
USA Investor Relations Karine Kleinhaus, M.D., M.P.H. Divisional VP, North-America Tel :+1-914-512-4109 karinek@pluristem.com
Visit Website